These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 22517104

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Marousi S, Travasarou M, Karageorgiou CE, Gheuens S, Koralnik IJ.
    Neurology; 2012 Nov 20; 79(21):2160; author reply 2160. PubMed ID: 23170016
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
    Tan IL, McArthur JC, Clifford DB, Major EO, Nath A.
    Neurology; 2011 Sep 13; 77(11):1061-7. PubMed ID: 21832229
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Minimal supportive treatment in natalizumab-related PML in a MS patient.
    Lalive PH, Bridel C, Ferfoglia RI, Kaiser L, Du Pasquier R, Barkhof F, Haller S.
    J Neurol Neurosurg Psychiatry; 2015 Mar 13; 86(3):354-5. PubMed ID: 24957322
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.
    Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag BM, Barkhof F, Killestein J, Dutch-Belgian Natalizumab-associated PML study group.
    J Neurol Neurosurg Psychiatry; 2016 Aug 13; 87(8):879-84. PubMed ID: 26369555
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.
    Igra MS, Paling D, Wattjes MP, Connolly DJA, Hoggard N.
    Br J Radiol; 2017 Jun 13; 90(1074):20160721. PubMed ID: 28362522
    [Abstract] [Full Text] [Related]

  • 18. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC.
    Neurology; 2013 Oct 15; 81(16):1400-8. PubMed ID: 24049136
    [Abstract] [Full Text] [Related]

  • 19. Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
    Tan LA, Lopes DK.
    J Clin Neurosci; 2015 Oct 15; 22(10):1669-71. PubMed ID: 26115897
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.